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AI: Augmentation Index 
BBB: Blood-brain barrier  
BP: Blood Pressure 
CSF: Cerebrospinal fluid  
FMD: Flow mediated vasodilation 
LP: Lumbar Puncture 
MAP: Mean Arterial Pressure  
MCI: Mild Cognitive Impairment 
PWV: Pulse Wave Velocity  
RHI: Reactive Hyperemia Index  
VTI: Velocity Time Integral  






Background: The rate of AD for AAs is 64% higher than for non-Hispanic White Americans 
(Whites). It is hypothesized that poor peripheral vascular function, in combination with genetics, 
stress and inflammation may directly contribute to the accumulation of AD pathologic biomarkers. 
These risk factors may disproportionately affect AAs.  
Objective: Our objective was to determine if in a healthy middle-aged cohort at risk for AD (1) 
AD biomarkers in CSF differ by race, (2) peripheral vascular dysfunction and cognition are 
related to a higher burden of CSF AD biomarkers, and (3) these relationships differ by race.   
Methods: We enrolled 82 cognitively normal, middle-aged (45 and older) adults including AAs 
and Whites at high risk for AD due to parental history. Study procedures included lumbar puncture, 
vascular ultrasound and cognitive testing.  
Results: While participants were in overall good health, AAs exhibited poorer indices of 
preclinical vascular health, including higher central SBP, central MAP, and EndoPAT AI, a marker 
of arterial stiffness. AAs also had significantly less CSF tau burden than Whites. After polynomial 
regression analysis, adjusted for age, gender, education, and ApoE4 status, race significantly 
modified the relationship between total tau, phospho-tau and Trails b, a marker of executive 
function. Small differences in tau correlated with poorer cognition in AAs. 
Conclusion: In a healthy middle-aged cohort at risk for AD, AAs had worse peripheral vascular 
health and worse cognition than Whites. Despite lower tau burden overall, race modified the 
relationship between tau and cognition, such that small differences in tau between AAs was related 
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BACKGROUND 
With the projected increase in Alzheimer’s disease (AD), there is increased urgency to find 
ways of preventing or delaying disease onset. Targeting modifiable risk factors in high risk 
populations may help slow AD progression, though no interventions targeting these factors 
currently exist. Midlife vascular risk factors, particularly hypertension, have been associated with 
increased risk of AD in later life [1-4]. Moreover, controlling blood pressure (BP) protects against 
AD [2, 5, 6], however, the mechanism of this relationship remains disputed.  
The rate of AD for African Americans (AAs) is 64% higher than for non-Hispanic White 
Americans (Whites) [7]. The reason is likely multi-factorial and includes sociocultural issues, 
psychological (i.e. stress and depression) genetics, and vascular risk factors. AAs have higher 
cardiovascular risk including  higher rates of hypertension, obesity, and diabetes [8]. Black race is 
also associated with impaired microvascular vasodilatory function, and greater large arterial wave 
reflections and stiffness, independent of cardiovascular risk [9]. AAs report higher levels of stress 
and depression which increases risk of AD [10-12]. [13]. Offspring of parents with AD are six 
times more likely to develop AD, and the presence of family history with APOE ɛ4 positivity 
increases lifetime risk of AD [14].  
 The relationship between arterial function and cognition in healthy and AD populations 
has been well documented. The mechanism for this is not fully understood, but research shows 
midlife vascular problems may impact late life cognitive decline and AD.  For example, reduced 
cardiac output during middle-age reduces cerebral blood flow and mediates Aβ accumulation and 




showed that midlife systolic BP variation is associated with increased Aβ in the hippocampus [16, 
17]. Uncontrolled BP may be linked to Aβ accumulation in midlife, eventually leading to neuronal 
atrophy and cognitive impairment[18]. Studies among AD and Mild Cognitive Impairment (MCI) 
patients have shown a relationship between poorer cognition and nighttime BP disruption, a 
common symptom among AD patients [19]. Abnormal nocturnal BP patterns and arterial stiffness 
are strong indicators of MCI, suggesting that arterial dysfunction may predict AD-related cognitive 
decline, and thus is a potential modifiable risk factor and therapeutic target for high risk individuals 
[20].  
 
Here we describe the rationale, and baseline results of the ASsociation between 
Cardiovascular Risk and PrecliNical Alzheimer’s Disease (ASCEND) Study. ASCEND is a 
longitudinal, two-year observational study of cognitively normal, middle-aged adults at risk for 
AD, due to a parental history and overrepresentation of the ApoE ɛ4 allele.  
The main objective of ASCEND was to determine the extent to which peripheral vascular 
function is related to CSF Aβ and tau levels and cognitive test performance over two years, and 
whether these relationships differ by race. We chose midlife because this is the time when AD 
neuropathology manifests, and when the negative impact of sustained vascular complications 
begin to have a lasting impact and arterial dysfunction begin Importantly, midlife is the optimal 
time to stage an intervention via modifiable risk factors, with the potential to both reduce the 
likelihood of cardiovascular events and reduce the probability of AD in later life.   
Herein, we report the baseline cross-sectional data comparing vascular function, cognition, 




will differ by race and (2) peripheral vascular dysfunction and cognition are related to a higher 
burden of CSF AD biomarkers, and (3) that these relationships differ by race.    
 
METHODS 
ASCEND study visit and design  
 We enrolled eighty-two middle-aged, (45 years or older) adult children of persons with 
AD. AD diagnosis was either autopsy-confirmed or probable AD as defined by NINDS-ADRDA 
criteria, and verified using the validated Dementia Questionnaire (DQ) [21] and medical records 
when available. Participants were recruited from the Emory Alzheimer’s Disease Research Center 
(ADRC) clinical cohort, physician referral, and through community events and received $100 
compensation. 
 Table 1 shows ASCEND visit procedures at each time point. Study duration was 2 years, 
with annual visits (baseline, Year 1 and Year 2) although we only report baseline results in this 
paper. Baseline visits included a fasting lumbar puncture (LP), vascular ultrasound, ambulatory 
blood pressure monitoring, blood draw and cognitive testing. Study visit duration was 6.5 hours 
and was split into 2 days if necessary.  
Inclusion Criteria: (i) a biological parent with AD; (ii) 45 – 65 years; (iii) willing to fast 
for eight hours; (iv) willing to undergo all procedures including LP. 
Exclusion Criteria: (i) contraindication for LP; (ii) significant neurologic disease; (iii) 
history of significant head trauma; (iv) Major untreated depression within two years; (v) history of 
alcohol or substance abuse; (vi) any significant systemic illness or unstable medical condition 




AD, MCI or residence in a skilled nursing facility; (viii) use of investigational medication; (ix) 




Cerebrospinal Fluid (CSF) Collection: Participants had CSF acquired via LP. CSF samples 
were collected after an 8-hour overnight fast and according to guidelines put forth in the 
“Biospecimens Best Practice Guidelines for the ADCs” [22]. Participants were placed in the sitting 
position and asked to maximally flex their knees, hips, back, and neck. The skin over L4-L5 was 
prepped and draped in a sterile manner. 1% lidocaine was used as a local anesthetic, followed by 
insertion of a spinal needle with introducer into the L4-L5 interspace using sterile technique. 
Approximately 22ml of CSF was collected using sterile polypropylene collection tubes. Samples 
underwent a light spin and aliquoted into 500µl polypropylene cryovials and stored at -80°C.  
CSF t-tau concentration was determined using a sandwich ELISA (Innotest hTAU-Ag, 
Innogenetics, Ghent, Belgium) specifically constructed to measure all tau isoforms irrespective of 
phosphorylation status, as previously described [23]. Tau phosphorylated at threonine 181 (P-tau) 
was measured using a sandwich ELISA method (Innotest phospho-tau (181P), Innogenetics, 
Ghent, Belgium), as previously described [24]. Aβ1–42 levels were determined using a sandwich 
ELISA (Innotest β-Amyloid(1–42), Innogenetics, Gent, Belgium), specifically constructed to 
measure Aβ containing both the first and 42nd amino acid, as previously described [25]. Samples 
were assayed in two batches by experienced and board-certified laboratory technicians. Intra-assay 





Vascular Ultrasound: Vascular measurements performed included pulse wave velocity 
(PWV), flow-mediated vasodilation (FMD) and pulsatile arterial tonometry (EndoPAT). Measures 
were chosen based on previous reports of vascular function and AD; preclinical variation in these 
measures may indicate vascular dysfunction before more overt clinical events occur, including 
hypertension or heart failure [20, 23].  
PWV, a measure of arterial stiffness, is highly reproducible and correlates with MCI, 
cardiovascular events and all-cause mortality [20, 24]. FMD measures arterial endothelial 
function using high-frequency ultrasound assessment of changes in brachial artery diameter 
during hyperemia, and is associated with cardiovascular risk [25, 26]. EndoPAT is used to assess 
hyperemic microvascular function. Importantly, these markers may give us a clearer window into 
early vascular dysfunction in a clinically healthy population.  
PWV: was measured using an AtCor SphymoCor Px tonometry system. A pressure 
transducer was placed on the skin at the point the arterial pulsation of the right common carotid 
and right radial arteries. A Millar micromanometer was in the tip of the probe. Using a generalized 
transfer function, the distance between these pressure points and the peripheral arterial waveforms, 
a central aortic pressure signal was derived, from which aortic augmentation index and pulse wave 
velocity were determined.   
FMD: Participants were placed in a supine position and an occlusion cuff was placed 
around the forearm. For each measurement, baseline images of the brachial artery 2–10cm above 
the antecubital fossa were assessed using a 13-MHz high-resolution ultrasound transducer 
(Acuson). Electrocardiogram gating was used to capture end-diastolic arterial diameters and the 
average diameter and blood flow velocity for three cardiac cycles was recorded for baseline values. 




deflated to create a flow stimulus in the brachial artery. Doppler ultrasound was used to measure 
peak hyperemic blood flow velocity 10 seconds after cuff release, and diameter measurements 
were captured at 60 and 90 seconds after cuff release. Calculations of FMD were based on the 60 
and 90 second measurements and at peak hyperemic diameters. Measurements were obtained by 
a trained sonographer. FMD is expressed as the % change in artery diameter from baseline: (peak 
hyperemic diameter − baseline diameter)/baseline diameter.  
EndoPAT: EndoPAT detects plethysmographic pressure changes in the finger tips caused 
by the arterial pulse and translates this to a peripheral arterial tone. Endothelium-mediated changes 
in vascular tone after occlusion of the brachial artery are reflecting as downstream hyperemic 
response, which is a measure for arterial endothelial function. EndoPAT was measured 
simultaneously with FMD. 
 
Ambulatory Blood Pressure Monitoring: The National Institute for Health and Clinical 
Excellence (NICE) Hypertension Guidelines of the United Kingdom recommend mean 24-hr 
ambulatory BP monitoring as a key priority in diagnosing hypertension [27]. Ambulatory measures 
provide a superior predictive value for cardiovascular events compared to clinic BP measurements 
and have been used in prior dementia research [19, 28-31]. 
  
Blood Collection: Participants underwent blood draw for ApoE genotyping. Venous blood 
was collected into EDTA anticoagulated tubes and genomic DNA was isolated by standard 
protocols. We isolated 50 to 70g of DNA from 2 mL of whole blood. ApoE genotypes were 




Inc) unique for each ApoE single-nucleotide polymorphism, rs429358 (assay ID C3084793 20) 
and rs7412 (assay ID C 904973 10), according to established protocols. 
 
Neuropsychological testing: Neuropsychological testing lasted one hour and included tasks 
selectively chosen to be used in a cognitively normal but high-risk sample. The battery provided 
assessment of several cognitive domains (memory, executive and visuospatial) including the 
Montreal Cognitive Assessment (MoCA) [32], Trail making test [33], Forwards and Backwards 
digit span memory test [34], Mental Rotation Test [35], Benson complex figure recall [36], 
Buschke memory test [37], and the Multilingual Naming Test (MINT) [38].  
 
Medical and Medication History including smoking history, education, income, hours of 
sleep, medications, history of diabetes, hypercholesterolemia, coronary artery disease, and 
hypertension were collected. 
 
Statistical Methods 
Demographic and clinical characteristics were summarized using descriptive statistics. 
Differences in categorical variables between AAs and Whites were analyzed by a chi-square test. 
Data normality of continuous variables was assessed by histogram and Shapiro-Wilk test. 
Differences for continuous variables between the two racial groups were compared with a two-
sample t-test for normally distributed data or Mann-Whitney U test for variables with non-normal 
distribution.  
The raw scores of all cognitive tests were transformed to Z scores. The resulting 




the raw scores. Natural-logarithm or square transformation was applied to AD biomarkers to better 
fit normal distribution.  
Polynomial multiple regressions were used to investigate associations between vascular 
function, AD biomarkers and cognitive test scores to detect curvilinearity in the relationship. To 
control the confounding factors, age, gender, race, education attainment and ApoE ɛ4 status were 
included in the regression models. To test if the association differed by race, an interaction between 
each of the vascular function indices or AD biomarkers and race was included in the models. 
Because multiple hypotheses were tested, the false discovery rate (FDR) method was used to 
correct for the multiple testing problem [39].   
All analyses were carried out in SAS 9.4. All tests performed were two-sided. 
 
RESULTS 
82 individuals were enrolled. One participant was lost to follow-up, and one withdrew from 
the study. Of the 80 remaining individuals, 30 were AA and 50 were White (Table 2). For AAs, 
mean age was 60.1 ± 7.9, 83.3% were female, and 51.7% were ApoE ɛ4 positive. For Whites, 
mean age was 58.5 ± 6.1, 56.0% were female, and 50.0% were ApoE ɛ4 positive. Education level 
was comparable, but income was higher in Whites (p<0.01). Smoking history and 
hypercholesterolemia were comparable between groups. More (57.1%) of AAs compared to of 
Whites (34.0%) had a history of hypertension (p=0.0472); 40.0% of AAs compared to 20.0% 
Whites (p=0.05) were taking antihypertensives. AAs reported 1.2 fewer hours of sleep on average 
(p<.01).  
In healthy individuals, t-tau<400, p-tau<80, Aβ-42>550, and Aβ-42/40>0.089. On average, 




CSF compared to Whites (p=0.0036, p=0.0055) (Table 3). AAs also had borderline lower Aβ1-40 
and significantly lower Aβ1-38 compared to Whites (p=0.07, p=0.03). (Table 3) 
Mean peripheral BP values were similar between groups and in the pre-hypertensive range 
[(127.6 ± 13.3)/ (77.3 ± 7.0) for AAs and (125.1 ± 12.3)/ (77 ± 9.0) for Whites] with no difference 
in nighttime BP patterns (Table 4). FMD, PWV, RHI, and central AI were comparable between 
groups, but EndoPAT AI (p=0.01) and central BP (p=0.017) were significantly higher in AAs 
compared to Whites, with central pressure trending higher in AAs (p=0.06).  
AAs performed more poorly on all cognitive tests compared to Whites, with significant 
differences in the MoCA, Trails B, Buschke delay, and MINT tests (p<0.01, p=0.02, p=0.02, 
p<0.01). (Table 5)  
After transformations for non-normally distributed data, we performed polynomial 
regression analyses between AD biomarkers and (a) cognition (b) peripheral vascular function, 
and (c) between peripheral vascular function and cognition. Race significantly modified the 
relationship between Z score of Trail b and t-tau and p-tau (false discovery rate p=0.0280 for both), 
after adjustment for age, gender, education and ApoE ɛ4 (Figures 1 and 2).  
 
DISCUSSION 
In this study, we present baseline data of the ASCEND study, a sampling of 30 AA and 50 
White, asymptomatic and middle-aged individuals at high-risk for AD due to parental history. 
Women were more proportionately represented in the AA group, and incomes were higher in the 
White cohort despite similar education levels. More AAs reported hypertension and 
antihypertensive medication use, coronary artery disease and diabetes, which is consistent with 




participants in both racial groups were ApoE ɛ4 positive, consistent with our and other studies in 
cohorts of adult children of AD individuals [6, 40]. 
Whites outperformed AAs on all cognitive tests, including global cognition, executive 
function, and verbal memory and language. Cognitive tests may have implicit cultural biases which 
favor Whites[41, 42]. Depression and stress, which result in poorer cognitive test performance, 
have higher incidences in AAs [43], however the incidence of both in our cohort did not differ by 
race. AAs did report less sleep than their White peers. Low and high blood pressures can also result 
in poorer performance, however our lowest recorded BP was 104/59 and the majority were in the 
normal or pre-hypertensive range. 
AAs had lower levels of tau (t-tau, p-tau) compared to Whites. This result was first reported 
in 2017 in older adults and proved true both in cognitively normal and cognitively impaired groups 
[40]. The finding was corroborated in 2019 in a larger population of adults which also included 
both cognitively normal and impaired individuals [44]. Our study is the first to report this in a 
cohort of middle-aged, cognitively normal adults at risk for AD. The fact that this discrepancy is 
present even during middle-age supports the hypothesis that AD neuropathology begins during 
middle-age before the clinical or cognitive symptoms of AD manifest. It is possible that race 
related differences in brain AD biomarkers exist. Further research is needed to ensure the 
appropriateness of tau and Aβ targeted therapies in both AAs and Whites, or whether modifications 
should be made based on race.  
Race significantly modified the relationship between tau (t-tau and p-tau) and executive 
function. Executive function is one of the first cognitive domains affected in AD, and tau has been 
correlated to MCI. It has previously been postulated that despite lower baseline levels of tau, AAs 




atrophy, and white matter hyperintensity [42]. Our results are cross-sectional and therefore we 
cannot report whether individuals are more sensitive to smaller changes in tau; however as a group, 
small differences in tau in AAs were related to worse cognition when compared to Whites. Morris 
et al. found a significant race by ApoE ɛ4 interaction for tau such that only ɛ4 positive participants 
showed racial differences [41]. Our cohort was strongly ApoE ɛ4 positive, yet even after adjusting 
for this we found the correlation between tau and Trails B to hold true. The finding that race 
modifies the relationship between tau and cognition implies that the neuropathology of tau 
deposition may differ in AAs, and there may need to be a lower threshold for treatment in these 
individuals. Existing cutoff values for CSF biomarkers may not be appropriate for AAs. 
We report that AAs have lower levels of amyloid beta Aβ-38. Both Aβ-40 and Aβ-38 
variants are more abundant in the brain than Aβ1-42. Future studies should investigate the role of 
these lesser studied forms of amyloid beta in AD pathology.  
While BP values were not different in AAs and Whites in our study, AAs self-reported 
more hypertension, antihypertensive medications and diabetes. However, BP was similar and in 
the pre-hypertensive range for both AAs and Whites, which makes the finding of microvascular 
differences still significant. A previous study of racial difference in microvascular health found 
that AAs had greater arterial wave reflections as assessed by EndoPAT AI and central AI, and 
greater arterial stiffness as assessed by PWV, even after adjustment for cardiovascular risk factors 
[9]. Our results for EndoPAT AI are similar although central AI and PWV differences were not 
significantly different in our smaller cohort, probably due to the smaller sample size. EndoPAT is 
a marker of arterial stiffness and has been shown to be related to white matter microstructure and 
executive function [43]. This is important because in our middle-aged cohort higher EndoPAT, i.e. 




relationship between EndoPAT and cognition in our baseline results, but it would be interesting to 
watch this relationship over the course of two years, or in future studies even longer. We found 
AAs had higher central systolic BP and central mean arterial pressures, as measured by pulse wave 
analysis. Central BP is generally ~10 mmHg lower than the peripheral BP, which was true in the 
White participants [44]. Interestingly, in the AA group, central BP was similar to peripheral BP 
and higher than in Whites. Pressures within the central aorta may be more relevant to 
cardiovascular outcome than pressures in the brachial artery, although its clinical relevance 
remains controversial [44, 45]. It is possible that aortic BP, rather than peripheral BP, might be an 
early mid-life difference of vascular risk for AAs specifically, even before development of clinical 
hypertension.   
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Table 1: ASCEND Study Visit Procedures 
 
 Baseline Year 1 Year 2 
Blood Draw X X X 
Vascular Ultrasound 
(EndoPAT, FMD, PWV) 
X X X 
Ambulatory Blood 
Pressure 
X X X 
CSF Collection X - X 
Neuropsychological 
Testing 







Table 2: Demographic characteristics 
 African American (n=30) White (n=50) p 
Age 60.1 ± 7.8 58.5 ± 6.1 0.30 
Gender (% female) 83.3%* 56.0% 0.0123* 
Education 10.7% High School/GED 
39.3% College graduate 
50.0% Post-graduate 
18.0% High School/GED 
38.0% College graduate 
44.0% Post-graduate 
0.68 









66.0% $80,000 or more 
0.0005* 
History of smoking 30.8% 28.0% 0.80 
History of diabetes 7.4%* 0% 0.05 
History of high 
cholesterol 
60.7% 58.0% 0.82 
History of coronary 
artery disease 
3.6%  0% 0.18 
History of hypertension  57.1%* 34.0% 0.0472* 
Anti-hypertensive user  40.0%* 20.0% 0.05 
Hours of sleep 6.0 ± 1.1* 7.2 ± 0.9 <0.0001* 






Table 3: Alzheimer’s Disease Biomarkers 
 





β –amyloid (pg/ml)    
Triplex Aβ1-38 2029.2 ± 672.9* 2466.3 ± 760.3 0.0268* 
Triplex Aβ1-40  5020.9 ± 1312.7 5750.0 ± 1618.2 0.07 
Triplex Aβ1-42  413.1 ± 107.5 419.9 ± 150.0 0.85 
ELISA Aβ1-42  722.0 ± 164.2 703.7 ± 197.3 0.71 
Tau (pg/ml)   p (Wilcoxen) 
t-tau  199.0 (166.0 – 244.0) 297.0* (228.0 – 423.0) 0.0036* 
p-tau  37.0 (34.0 – 42.0) 48.0* (37.0 – 64.0) 0.0055* 
*p<0.05 
Aβ1-42/ Aβ1-40, t-tau, and p-tau were non-parametric and necessitated use of Wilcoxen tests. Reported values for 





Table 4: Vascular risk factors 
 





Ambulatory Blood Pressure     
Systolic (mmHg) 127.6 ± 13.3 125.1 ± 12.3 0.42 
Diastolic (mmHg) 77.3 ± 7.0 77.3 ± 9.0 0.99 
Endothelial Function                                 
FMD (%) 6.4 ± 5.2 5.3 ± 4.5 0.33 
VTI (cm) 7.3 ± 2.9 6.2 ± 2.4 0.10 
Peak velocity (cm/s) 1.1 ± 0.6 1.1 ± 0.4 0.59 
EndoPAT- RHI  2.3 ± 0.7 2.3 ± 0.7 0.89 
EndoPAT- AI (%) 33.9 ± 19.9* 22.0 ± 17.1 0.0102* 
PWV (m/s) 7.6 ± 1.5 7.3 ± 1.3 0.36 
Central Systolic (mmHg)  121.2 ± 19.5* 110.8 ± 12.5 0.0174* 
Central Diastolic (mmHg) 79.1 ± 13.0 75.1 ± 10.7 0.16 
Central MAP units (mmHg) 96.5 ± 14.7 90.3 ± 10.4 0.06 






Table 5: Cognitive testing  





MoCA 25.0 (24.0 – 27.0)*  27.0 (25.0 – 29.0) 0.0051* 
Trails B 81.0 (69.0 – 101)* 70.0 (56.0 – 82.0) 0.0239* 
Forwards Digit Span 6.5 (5.5 – 7.0) 7.0 (6.0 – 8.0) 0.22 
Backwards Digit Span 4.0 (3.0 – 5.0) 5.0 (4.0 – 6.0) 0.10 
Mental Rotation 17.5 (15.0 – 20.0) 18.5 (13.0 – 21.0) 0.50 
Benson Delay 12.0 (10.0 – 14.0) 12.0 (10.0 – 13.0) 0.28 
Buschke Delay 6.0 (2.0 – 8.0)* 7.0 (5.0 – 9.0) 0.0218* 
MINT 29.0 (28.0 – 31.0)* 31.0 (30.0 – 32.0) 0.0017* 
*p<0.05 






Figure 1 Relationship between Trail B and Total Tau in African Americans and Whites Adjusted 






Figure 2 Relationship between Trail B and Phospho-Tau in African Americans and Whites 
Adjusted for Age, Gender, Education Attainment and ApoE4 Status 
 
 
 
 
